文献速递多重用药衰弱、肌少症与跌倒

老年人群处方精简的新视野

New horizons in deprescribing for older people.
PubMed 文献 · Age Ageing · 2019-01-01

本文综述老年多重用药与处方精简。老年人尤其衰弱者药物疗效更低、不良反应风险更高,药物不良反应常被忽视并触发进一步处方。处方精简应基于共享决策,现有试验提示常可无害实现,可减少多重用药、改善依从性、降低费用和改善生活质量,但住院或死亡率改善证据少。

要点

  • 衰弱老年人药物疗效更低且不良反应风险更高,不良反应常被忽视并触发进一步处方。
  • 处方精简应基于共享决策,现有试验提示常可无害实现。
  • 证据提示可减少多重用药、改善依从性、降低费用和改善生活质量,住院或死亡率改善证据少。

核心结论

  • 处方精简应基于共享决策,现有试验提示常可无害实现,但住院或死亡率改善证据少。

研究设计与样本

  • 本文为综述,未报告系统检索范围与样本量。

主要发现

  • 老年人尤其衰弱者药物疗效更低且不良反应风险更高,原因包括衰弱生理效应、药物相互作用、药物-疾病相互作用和依从性降低。
  • 药物不良反应常被忽视并可触发进一步处方。
  • 某些药物已被认为对衰弱者可能不适当,但使用仍常见。
  • 证据提示许多老年人对减少药物持开放态度。
  • 现有试验提示处方精简常可无害实现,可减少多重用药、改善依从性、降低费用和改善生活质量,但住院或死亡率改善证据少。

临床怎么用

  • 处方精简应基于共享决策。
  • 需要处方与给药所有相关方之间良好团队协作与沟通,并借助改进的卫生信息学支持。
  • 应促进非药物方法。

局限性

  • 现有证据基础有限,住院或死亡率改善证据少。
  • 需扩大证据基础并提高公众和临床医生对处方精简潜在益处的认识。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Deprescribing has gained interest recently, driven by an ageing population seeing an increasing number living with multiple long-term conditions. This, coupled with disease-specific guidelines derived from clinical trials in younger people, has led to an increase in exposure to polypharmacy and the associated therapeutic burden. Older people, especially those living with frailty, tend to experience lower efficacy of these medications along with a higher risk of drug adverse effects. Explanations for these differences include the physiological effects of frailty, drug-drug interactions, drug-disease interactions and reduced medication adherence. Adverse drug reactions often go unnoticed and can trigger further prescribing. Certain medications have been recognised as potentially inappropriate for people with frailty, yet their use remains common. Evidence suggests that many older people are open to the concept of reducing medications. Deprescribing should be based around a shared decision-making approach. Trials to date have suggested that it can often be achieved without harm. To date, there are few data to support improvements in hospitalisation or mortality rates. However, there is some evidence that it may reduce polypharmacy, improve medication adherence, reduce financial costs and improve quality of life. In the future, it will be necessary to grow the evidence base and improve public and clinician awareness of the potential benefits of deprescribing. It will require excellent team working and communication between all of those involved in the prescribing and administration of medications, also supported by improved healthcare informatics. Non-pharmacological approaches will need to be promoted. Fewer drugs is not less care.

来源:Age Ageing,查看原文。版权归原作者所有。

引用

  1. Woodford HJ, Fisher J. New horizons in deprescribing for older people. Age Ageing. 2019. PMID: 31595290. doi:10.1093/ageing/afz109

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。